Overview

Study of XB002 in Subjects With Solid Tumors

Status:
Recruiting
Trial end date:
2024-10-07
Target enrollment:
Participant gender:
Summary
This is a Phase 1, non-randomized, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w as a monotherapy to subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Exelixis